Undiscovered Gems in India to Watch This September 2024

Over the last 7 days, the Indian market has risen 2.5%, and over the past 12 months, it is up an impressive 46%. With earnings forecast to grow by 17% annually, identifying promising stocks that align with these robust market conditions can be particularly rewarding.

Top 10 Undiscovered Gems With Strong Fundamentals In India

Name	Debt To Equity	Revenue Growth	Earnings Growth	Health Rating
Vidhi Specialty Food Ingredients	7.27%	11.00%	4.02%	★★★★★★
3B Blackbio Dx	0.38%	-0.88%	-1.47%	★★★★★★
Yuken India	27.96%	12.35%	-44.41%	★★★★★★
Bharat Rasayan	8.15%	0.10%	-7.93%	★★★★★★
TechNVision Ventures	100.73%	20.37%	68.50%	★★★★★★
Voith Paper Fabrics India	0.07%	10.95%	9.70%	★★★★★☆
Indo Tech Transformers	2.30%	22.05%	60.31%	★★★★★☆
Piccadily Agro Industries	50.57%	13.86%	42.85%	★★★★★☆
Macpower CNC Machines	0.40%	22.04%	31.09%	★★★★★☆
Share India Securities	24.23%	37.59%	48.98%	★★★★☆☆

Click here to see the full list of 475 stocks from our Indian Undiscovered Gems With Strong Fundamentals screener.

Underneath we present a selection of stocks filtered out by our screen.

Arkade Developers (NSEI:ARKADE)

Simply Wall St Value Rating: ★★★★★☆

Overview: Arkade Developers Limited operates as a real estate development company in India with a market cap of ₹28.89 billion.

Operations: Arkade Developers generates revenue primarily from real estate development, amounting to ₹6.35 billion.

Arkade Developers recently completed an IPO raising INR 4.1 billion, a notable step for the company. Over the past year, earnings surged by 141.9%, significantly outpacing the Real Estate industry’s 24.1% growth rate. The company's net income for FY2024 was INR 1,228 million compared to INR 508 million last year, with basic earnings per share at INR 8.08 from INR 3.34 previously. Arkade's EBIT covers interest payments by a strong factor of 12x and its net debt to equity ratio stands at a satisfactory level of 14%.

• Click here to discover the nuances of Arkade Developers with our detailed analytical health report.

• Review our historical performance report to gain insights into Arkade Developers''s past performance.

JSW Holdings (NSEI:JSWHL)

Simply Wall St Value Rating: ★★★★★☆

Overview: JSW Holdings Limited, a non-banking financial company, primarily engages in investing and financing activities in India with a market capitalization of ₹104.61 billion.

Operations: JSW Holdings generates revenue primarily from investing and financing activities, amounting to ₹1.71 billion. The company's net profit margin stands at 92%.

JSW Holdings has shown mixed performance recently, with revenue for Q1 2024 at INR 272.32 million and net income rising to INR 525.81 million from INR 243.57 million a year ago. The company reported basic earnings per share of INR 47.38 compared to INR 21.95 last year, reflecting significant growth despite a negative earnings trend (-47.5%) over the past year versus the industry average of 63.2%. Notably, JSW Holdings is debt-free and was recently added to the S&P Global BMI Index on September 23, 2024, enhancing its market visibility.

• Click to explore a detailed breakdown of our findings in JSW Holdings' health report.

• Gain insights into JSW Holdings' historical performance by reviewing our past performance report.

Marksans Pharma (NSEI:MARKSANS)

Simply Wall St Value Rating: ★★★★★★

Overview: Marksans Pharma Limited, along with its subsidiaries, focuses on the research, manufacturing, marketing, and sale of pharmaceutical formulations across various international markets including the United States, North America, Europe, the United Kingdom, Australia, and New Zealand; it has a market cap of ₹142.37 billion.

Operations: Marksans Pharma Limited generates revenue primarily from its pharmaceutical formulations segment, which amounted to ₹22.68 billion. The company operates across various international markets, contributing to its overall financial performance.

Marksans Pharma has shown strong financial health, with its debt to equity ratio improving from 19.9% to 11.7% over the past five years. Its earnings growth of 21.7% outpaced the industry average of 19.2%, and EBIT covers interest payments by 32 times, indicating robust profitability. Recent news includes a dividend declaration of INR 0.60 per share and successful USFDA inspection closure, positioning Marksans for potential M&A activities in Europe to drive further growth.

• Click here and access our complete health analysis report to understand the dynamics of Marksans Pharma.

• Understand Marksans Pharma's track record by examining our Past report.

Where To Now?

• Embark on your investment journey to our 475 Indian Undiscovered Gems With Strong Fundamentals selection here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com